Daiichi Sankyo Company, Limited

Kyoto Pharmaceutical Industries, Ltd.

Rieko Takano

Shinji Ashida

Mitsuhiro Iwamoto

Koji Matsumoto

Masahiro Inoue

Narihiro Toda

Takahiro Katagiri

Takeshi Shida

Mami Yamazaki

Takeshi Honda

Ken Ishii

Masao Yoshida

Masaharu Inui

Masaki Miyazaki

Ryutaro Nakashima

Junya Kawai

Yoshihiro Ogura

Masafumi Ofuku

Shunsuke Takashima

Wakana Yokozeki

Masaya Fujii

Masafumi Ando

Teppei Fujimoto

Kazuya Otake

The present invention aims to provide a medicament capable of treating and/or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1): wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the aforementioned compound, for the prophylaxis and/or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.

Benzotriazole compound

To find a therapeutic and/or prophylactic agent for gastrointestinal disorders and so on, the agent having excellent activity and high safety. A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents an optionally substituted phenylene group; B represents an optionally substituted 4- to 10-membered heterocyclic group, an optionally substituted C6-C10 aryl group, or an optionally substituted C3-C10 cycloalkyl group; Rrepresents a hydrogen atom or a C1-C3 alkyl group; Rrepresents a hydrogen atom or a C1-C3 alkyl group; Rrepresents a C1-C6 alkyl group, a C3-C10 cycloalkyl group, a C1-C3 alkoxy C1-C3 alkyl group, or a C1-C3 hydroxyalkyl group; Rrepresents a hydrogen atom, a C1-C6 alkyl group, or a halogen atom; n represents an integer of 1 to 4; and X represents methylene, &#x2014;O&#x2014;, &#x2014;NH&#x2014;, &#x2014;N(C1-C3 alkyl)-, &#x2014;C(&#x2550;O)&#x2014;, &#x2014;S&#x2014;, &#x2014;S(O)&#x2014;, &#x2014;S(O)&#x2014;, or a single bond. 

Piperazinyl cyclohexane compounds as GPR38 agonists

Piperazinyl methyl phenyl cyclohexane compound

To find a therapeutic agent and/or a preventive agent for diabetes mellitus or the like having excellent activity and safety. A compound represented by the following general formula (I), or a pharmacologically acceptable salt thereof. In the formula, X represents &#x2550;C(R5)- or &#x2550;N&#x2014;; Y represents &#x2014;O&#x2014; or &#x2014;NH&#x2014;; L represents a bond or a substitutable C1-C3 alkylene group; M represents a substitutable C3-C10 cycloalkyl group, a substitutable C6-C10 aryl group, or a substitutable heterocyclic group; Rrepresents a C1-C6 alkyl group, a C3-C10 cycloalkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 aliphatic acyl group, a C1-C6 alkoxy C1-C6 alkyl group, or a C6-C10 aryl group; and R, R, R, and Rmay be the same or different and each represent a hydrogen atom, a halogen atom, a C1-C3 alkyl group, a C1-C3 haloalkyl group, a C1-C3 alkoxy group, or a nitro group. In this connection, the alkyl group moieties of Rand Rmay be bonded to each other to form a 5- to 6-membered heterocyclic ring containing one oxygen atom. 

Carboxylic acid compound

Growing community of inventors

Tokyo, Japan

Rieko Takano